Human Serum Albumin (DB00062) Approved Drug

Slides:



Advertisements
Similar presentations
Electrolyte solutions: Milliequivalents, millimoles and milliosmoles
Advertisements

Water & The Body Fluids 60% of adult body weight -Water makes up ¾ of the weight of lean tissue -Water makes up ¼ of the weight of fat Copyright 2005.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 27 Fluids and Electrolytes.
Fluids and Electrolyte Balance There is daily fluid intake and fluid out put *fluid intake: Its from two main sources 1-Exogenous Water is either drunk.
Overview of Profiling for Hemodialysis
Overview of Profiling for Hemodialysis
Selected Clinical Calculations
Fluid and Electrolyte Therapy. Introduction: The molecules of chemical compounds in solution may remain intact, or they may dissociate into particles.
BICARBONATE SODIUM Abrar Saleh Mai Mahfouz. Pharmacology Sodium bicarbonate is a buffering agent that reacts with hydrogen ions to correct acidemia and.
Colloid versus Crystalloid in Hypovolemic Shock Controversy
Introduction:  The preparation of parenteral admixture usually involves the addition of one or more drugs to large volume solutions such as intravenous.
Fluids replacement Professor Magdy Amin RIAD Professor of Otolaryngology. Ain shames University Senior Lecturer in Otolaryngology University of Dundee.
E Stanton RN MSN/ED, CEN, CCRN, CFRN
Fluid and Electrolyte Imbalance Acid and Base Imbalance
General Surgery Mosul university- College of dentistry-oral & maxillofacial surgery department Dr. Ziad H. Delemi B.D.S, F.I.B.M.S (M.F.) Fluid Therapy.
CTVT pgs A&A pgs (Anesthetist). Indications for Fluid Administration Hypovolemia.
MCQ – I V INDUCTION AGENTS
Follitropin beta (DB00066) Approved Drug
Antihemophilic Factor
Brodalumab Drugbank ID : DB11776 Molecular Weight (Daltons) :144,000
Darbepoetin alfa Drugbank ID : DB
Desirudin Drugbank ID : DB11095.
Reteplase Drugbank ID : DB00015
Serum albumin Albunex Optison™ IV infusion
Poractant alfa Drugbank ID : DB09113
IV Fluids Intravenous Fluids
Epoetin alfa Drugbank ID : DB00016
Elotuzumab Drugbank ID : DB06317.
Prothrombin complex concentrate
Anistreplase Drugbank ID : DB00029
Alemtuzumab (DB00087) Approved and Investigational Drug
Pegvisomant(DB00082) Approved Drug
Metreleptin Drugbank ID :DB09046
Insulin, porcine (DB00071) Approved Drug
Muromonab (DB00075) Approved and Investigational Drug
Insulin Degludec Drugbank ID :DB09564
Salmon Calcitonin Drugbank ID : DB00017
RAXIBACUMAB DB08902 C6320H9794N1702O1998S kDa CATEGORY
Serum Albumin Iodinated(DB00064) Approved Drug
Evolocumab Drugbank ID : DB09303.
Streptokinase (DB00086) Approved Drug
Natalizumab (Approved, Investigational)
Cetuximab Drugbank ID : DB00002
Intravenous Fluid Administration
Pegfilgrastim Drugbank ID : DB00019
Plasma Protein Fraction
Imiglucerase Protein chemical formula : C2532H3854N672O711S16
Protein average weight : Half life: 14.7 ± 10.4 hrs
Galsulfase (Approved investigational) DB01279
Asparaginase Drugbank ID : DB00023
Idarucizumab Molecular Weight (Daltons) : 47766
Fluid Replacement Therapy
Ibritumomab(DB00078) Approved Drug
Sebelipase alfa Protein chemical formula : C1968H2945N507O551S15
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Fluid Therapy General Surgery Dr. Ziad H. Delemi
Pegademase bovine Drugbank ID : DB00061
Anthrax immune globulin human
Ixekizumab Drugbank ID : DB11569 Molecular Weight (Daltons) :146,158
Fluid and Electrolyte Therapy
Tositumomab (DB00081) Approved Drug
Eptifibatide (DB00063) Approved and Investigational Drug
Presented by Chra salahaddin MSc in clinical pharmacy
Electrolyte solutions: Milliequivalents, millimoles and milliosmoles
Fluid Balance, Electrolytes, and Acid-Base Disorders
Fluid and Electrolyte Therapy
Buffered Solutions.
INTRAVENOUS FLUIDS Batool Luay Basyouni
Aspirin & NSAID.
Plasma expanders Dept. of Pharmacology CIPS.
Presentation transcript:

Human Serum Albumin (DB00062) Approved Drug Chemical Formula: C2936H4624N786O110S41 Molecular Weight: 66472.2 Human serum albumin isolated from expired blood plasma Indication/Usage For treatment of severe blood loss, hypervolemia, hypoproteinemia Pharmacodynamics Regulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation. Mechanism Of Action Acts as a high molecular weight, very soluble osmolyte Category Serum Substitutes Affected Organisms Humans and Mammals.

Experimenatl Properties Sequence MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL Experimenatl Properties Melting Point-62 °C Hydrophobicity: 0.395 Isoelectric Point: 5.67 Targets Apolipoprotein E,Serum amyloid A-1 protein,Protein AMBP Marketed Brands Albuminar: CSL Behring Albutein: GRIFOLS

Albuminar Formulation Used/Prescribed for Dosage Contraindications Albuminar is a sterile aqueous solution of albumin obtained from large pools of adult human venous plasmaby low temperature controlled fractionation according to the Cohn process. It is stabilized with 0.02 M sodium acetyltryptophanate and 0.02 M sodium caprylate and pasteurized at 60°C for 10 hours. Albumin (Human) 25%, is a sterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled fractionation according to the Cohn process. It is to be administered by the intravenous route. Formulation Albumin (Human) 25% (albumin human) is a solution containing in each 100 mL, 25 grams of serum albumin, osmotically equivalent to 500 mL of normal human plasma. The pH of the solution is adjusted with sodium bicarbonate, sodium hydroxide, or acetic acid. Approximate concentrations of significant electrolytes per liter are: sodium - 130-160 mEq; and potassium - n.m.t. 1 mEq. Used/Prescribed for precscribed in treatment of Shock, Burns, Hypoproteinemia with or without edema Dosage Albumin (Human) 25%, Albuminar®-25 (albumin (human)) may be given intravenously without dilution or it may be diluted with normal saline or 5% dextrose before administration. 200 mL per liter gives a solution which is approximately isotonic and iso-osmotic with citrated plasma. Contraindications Albumin (Human) 25% may be contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin. Side-effects Allergic or pyrogenic reactions are characterized primarily by fever and chills; rash, nausea, vomiting, tachycardia and hypotension have also been reported. if administered rapidly, may result in vascular overload with resultant pulmonary edema..

Albutein References Formulation Used/Prescribed for Dosage http://www.rxlist.com/albuminar-drug.htm Albutein Albutein is a concentrate of plasma proteins from human blood. It works by increasing plasma volume or serum albumin levels. Albutein® 20% is a sterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). Formulation Albutein® 20% is clinically desirable, compatible diluents include sterile 0.9% Sodium Chloride solution or sterile 5% Dextrose in Water. Used/Prescribed for For treatment of hypovolemic shock,As an adjunct in hemodialysis for patients undergoing long-term dialysis or for those patients who are fluid-overloaded and cannot tolerate substantial volumes of salt solution for therapy of shock or hypotension Dosage Albutein® 20% is administered intravenously. The total dosage will vary with the individual. In adults, an initial infusion of 100 mL is suggested.  Contraindications Albutein® 20% is contraindicated in patients with severe anemia or cardiac failure in the presence of normal or increased intravascular volume. Side-effects The most common adverse reactions include fever and chills, rash, nausea, vomiting, tachycardia and hypotension. Should an adverse reaction occur, slow or stop the infusion for a short period of time which may result in the disappearance of the symptoms. If administration has been stopped and the patient requires additional Albutein® 20%, material from a different lot should be used.

References Peters, T., Jr., Serum Albumin in: The Plasma Proteins, 2nd Ed., Putnam F.W. (ed), New York, Academic Press, 1:133-181, 1975. Finlayson, J.S., Albumin Products Semin Thromb Hemo, 6:85-120, 1980.